Taysha Gene Therapies (TSHA) Cash from Operations (2020 - 2026)
Taysha Gene Therapies (TSHA) posted Cash from Operations of 40878000.0 for Q1 2026, down 52.98% sequentially from 26722000.0 in Q4 2025, and down 85.64% YoY from 284672220.11 in Q1 2025.
Taysha Gene Therapies (TSHA) Cash from Operations (2020 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Cash from Operations for 7 years, with the latest figure at 40878000.0 in Q1 2026.
- Quarterly Cash from Operations fell 85.64% year-over-year to 40878000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 111948000.0 (down 34.15% YoY) and the FY2025 annual result came in at 93090000.0, down 14.61% from the prior year.
- Cash from Operations fell to 40878000.0 in Q1 2026 per TSHA's latest filing, from 26722000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 14712000.0 in Q4 2022 and troughed at 40939000.0 in Q1 2022.
- A 5-year average of 22153000.0 and a median of 21504000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations surged 136.54% in 2022, then plunged 209.55% in 2023.
- Over 5 years, Cash from Operations stood at 14712000.0 in 2022, then slumped by 209.55% to 16117000.0 in 2023, then fell by 13.59% to 18308000.0 in 2024, then slumped by 45.96% to 26722000.0 in 2025, then plunged by 52.98% to 40878000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 40878000.0, 26722000.0, and 24166000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | -40.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40.43 Mn |
| Jun 30, 2026 | -40.43 Mn |
| Mar 31, 2026 | -40.88 Mn |
| Mar 31, 2026 | -40.88 Mn |
| Dec 31, 2025 | -26.72 Mn |
| Dec 31, 2025 | -26.72 Mn |
| Sep 30, 2025 | -24.17 Mn |
| Sep 30, 2025 | -24.17 Mn |
| Jun 30, 2025 | -20.18 Mn |
| Jun 30, 2025 | -20.18 Mn |
| Mar 31, 2025 | -22.02 Mn |
| Mar 31, 2025 | -22.02 Mn |
| Dec 31, 2024 | -18.31 Mn |
| Dec 31, 2024 | -18.31 Mn |
| Sep 30, 2024 | -21.62 Mn |
| Sep 30, 2024 | -21.62 Mn |
| Jun 30, 2024 | -21.50 Mn |
| Jun 30, 2024 | -21.50 Mn |
| Mar 31, 2024 | -19.80 Mn |
| Mar 31, 2024 | -19.80 Mn |